Skip to main content
Presentation
View our ESMO GI 2026 presentation by visiting our publications page

Publications

Publishing the Frontiers of Immuno-Oncology

Spotlight Publication

Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)

Botensilimab ± Balstilimab in Patients with Advanced Cutaneous Melanoma Refractory/Resistant to Anti–PD-(L)1 ± CTLA-4: A Phase 2 Trial

May 31, 2026
,
Atkins, M. et al.
ASCO
Phase II Trial
Melanoma
View Publication
All Molecules
This is some text inside of a div block.
All Conferences
This is some text inside of a div block.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Clinical Trials
Clear all filters
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Balstilimab (PD-1 inhibitor)
Botensilimab (Fc-enhanced anti-CTLA-4)

Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer.

ESMO
European Society for Medical Oncology, Gastrointestinal (ESMO- GI)
July 28, 2022
,
Bullock, et al.
Colorectal (CRC)
Read Now
Download Now
View Presentation
AGENT-797 (Allogeneic iNKT Cell Therapy)

AgenT-797, a native allogeneic “off-the-shelf” iNKT cell therapy product shows anti-tumor activity in preclinical xenograft models.

SITC
Society for Immunotherapy of Cancer (SITC)
June 2, 2022
,
Yigit, et al.
No items found.
Read Now
Download Now
View Poster
AGENT-797 (Allogeneic iNKT Cell Therapy)

AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing.

SITC
Society for Immunotherapy of Cancer (SITC)
June 2, 2022
,
Burcu, et al.
No items found.
Read Now
Download Now
View Poster
INCAGN2385 (LAG-3 Antagonist)

INCAGN02385 is an Antagonist Antibody Targeting the Co-Inhibitory Receptor LAG-3 for the Treatment of Human Malignancies.

AACR
American Association for Cancer Research (AACR)
June 2, 2022
,
Savitsky, et al.
No items found.
Read Now
Download Now
View Poster
Agenus Inc.
3 Forbes Road
Lexington, MA 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200
Our Science
Pipeline
Publications
Clinical Trials
Immunotherapy
About BOT + BAL
Company
Our History
Our Team
Careers
Partners
Access
Patient Access
Contact Medical Affairs
Resources
Press Releases
In the News
Patient Resources
FAQs
Investors
Investor Overview
Events
Financial Information
Opt-out preferencesCookie PolicyTerms and Conditions of UsePrivacy PolicyCommunity GuidelinesAccess to Investigational Medicines PolicyReport Adverse EventInvestor Portal
© 2025 Agenus Inc. All rights reserved.